CClinicalTrials.gg
CompletedNCT00107627Updated Jun 25, 2009

Skin Incision Study - Closure of Skin Incisions in Gynecological Cancer Surgery

A Phase 3 interventional study of Caprosyn subcuticular sutures. and Monocryl subcuticular sutures. in Cancer, sponsored by Queensland Centre for Gynaecological Cancer. Completed at 2 sites in Australia. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-06-25.

Sponsored by Queensland Centre for Gynaecological Cancer · Phase 3 and Interventional

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The Skin Incision Study evaluates the efficacy of skin closure methods: skin staples and subcuticular sutures at 6 weeks and at 3 months following the operation by measuring cosmesis and pain.

Read the detailed description

The Surgical Skin Incisions (SSI) is an investigator initiated, randomized, prospective (pilot) study comparing methods of skin closure following gynecological cancer surgery to evaluate:

  • cosmesis;
  • pain;
  • adverse events.

The two most common methods of skin incision closure are staples or subcuticular sutures. Adverse events to surgical incisions represent major and significant burdens to patients and the health care system; however, no data is available comparing methods of skin closure. Surgeons have traditionally had to use personal belief rather than data or evidence to choose the method of skin incision closure. This study evaluates three types of skin closure methods:

  • Skin staples;
  • Monocryl subcuticular sutures;
  • Caprosyn subcuticular sutures.

The objective of this trial is to evaluate the efficacy of sutures and staples at 6 weeks and at 3 months following the operation by measuring cosmesis and pain. These are assessed by both the patient and the surgeon independently using linear analogue scales and by collecting information on analgesic medications taken by the patient. The safety of the staples and sutures will be expressed by the incidence of adverse events following surgery. Post-operative events such as wound infection, other wound complications, grade of inflammation, hemorrhage and other complications will be graded according to the Common Toxicity Criteria (CTC version 3) and recorded.

Investigators will invite public patients with proven or suspected gynecological cancer from Royal Brisbane and Women's Hospital and Mater Hospital (RBWH) that are booked to have elective surgery and that meet the selection criteria to participate in this study.

This is a pilot study to generate data for a definitive randomized study. Ninety (90) patients are required for recruitment to the pilot study.

The type of closure method patients will receive will be allocated using a randomization process. Three equally sized study arms of 30 patients will have their surgical incision closed with either surgical staples, Monocryl or Caprosyn. Additionally, patients will be stratified by site so as to remove selection bias.

All tests and assessments before and after the operation are standard of care. These results will be recorded. No additional tests or assessments will be performed for the aim of this trial.

Randomization, data management and statistical analysis will be coordinated by the Queensland Centre for Gynaecological Cancer. Statistical analysis will include calculating mean values and standard deviations for scores for each group at each assessment. Chi-square tests will be used to compare differences in proportions of patients who did or did not experience adverse events at each time point.

Results of this trial will be presented at scientific meetings at a national and international level and at educational meetings with medical staff. The results of this trial will also be submitted for publishing. The study will generate data for a definitive randomized study.

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • Gynaecological Cancer
  • Surgical Staples
  • Subcuticular Sutures
03

In context

Surgical Wound

519 studies on the registry are indexed under Surgical Wound; 71 are open to participants now.

This study's enrollment of 90 is above the median of 80 across 412 interventional studies indexed under Surgical Wound.

Browse Surgical Wound studies →

Lead sponsor

Queensland Centre for Gynaecological Cancer is the lead sponsor of 18 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Public patients at RBWH and at the Mater Public Hospital booked for elective surgery (laparotomy)
  • Surgery for suspected or proven gynecological cancer
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Patient compliance and geographic proximity that allow adequate follow-up
  • Signed written informed consent
  • Females >=18 years of age

Exclusion criteria

Exclusion Criteria:

  • Unplanned laparotomy
  • Laparoscopic procedures
  • Unwillingness of the patient to participate in the trial
  • Non-compliance of participant
  • Unavailability for follow-up
  • Patients who are unable or unwilling to give informed consent
05

Study design

Phase
Phase 3
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Active comparator
    1

    Skin staples;

    Other: Skin staples;

  • Active comparator
    2

    Monocryl subcuticular sutures.

    Other: Monocryl subcuticular sutures.

  • Active comparator
    3

    Caprosyn subcuticular sutures.

    Other: Caprosyn subcuticular sutures.

Interventions

  • OtherCaprosyn subcuticular sutures.

    Caprosyn subcuticular sutures.

    Also known as: Sutures, Stitches

  • OtherMonocryl subcuticular sutures.

    Monocryl subcuticular sutures.

    Also known as: Sutures,, Stitches

  • OtherSkin staples;

    Skin staples;

    Also known as: Staples

06

What researchers measure

Primary outcomes

  1. Efficacy of the device as measured by cosmesis, pain and requirement for analgesic and antibiotic medication

    Time frame: 6 weeks after surgery

Secondary outcomes

  1. To evaluate the wound healing process (normal or delayed), cosmesis and pain, requirement for surgical or medical intervention (analgesic and antibiotic medication)

    Time frame: 3 months after surgery

  2. Safety of the device as expressed in the incidence of adverse events following surgery

    Time frame: 6 weeks after surgery

07

Study locations

2 sites
  • QCGC, Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Mater Adult Public Hospital
    South Brisbane, Queensland 4101, Australia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 25, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00107627
Lead sponsor
Queensland Centre for Gynaecological Cancer
First posted
Apr 7, 2005
Start date
Mar 2005
Primary completion
Mar 2006
Completion
Mar 2006
Last update
Jun 25, 2009

Study contacts

Andreas Obermair
principal investigator · Queensland Centre for Gynaecological Cancer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion